Thomas Höger
Amministratore Delegato presso Apogenix AG
Posizioni attive di Thomas Höger
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Apogenix AG
 Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Amministratore Delegato | 01/11/2005 | - |
Storia della carriera di Thomas Höger
Precedenti posizioni note di Thomas Höger
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| DZ Bank AG (Securities) | Analyst-Equity | - | - |
| BASF SE | Corporate Officer/Principal | 01/01/1992 | - |
Knoll AG
 Knoll AG Pharmaceuticals: MajorHealth Technology Part of BASF SE, Knoll AG develops pharmaceuticals. The company is based in Haren, Germany. | Corporate Officer/Principal | - | - |
Statistiche
Distribuzione geografica
| Germania | 5 |
Posizioni
| Corporate Officer/Principal | 2 |
| Chief Executive Officer | 1 |
| Analyst-Equity | 1 |
Settori
| Health Technology | 3 |
| Finance | 2 |
| Producer Manufacturing | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| BASF SE | Producer Manufacturing |
| Aziende private | 3 |
|---|---|
Apogenix AG
Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Health Technology |
Knoll AG
Knoll AG Pharmaceuticals: MajorHealth Technology Part of BASF SE, Knoll AG develops pharmaceuticals. The company is based in Haren, Germany. | Health Technology |
| DZ Bank AG (Securities) | Finance |
- Borsa valori
- Insiders
- Thomas Höger
- Esperienza
